Quality control in cervical cancer screening in the UK should target false negatives
This article was originally published in Clinica
The number of false negative results detected under the UK cervical screening programme could be reduced if the focus of quality assurance systems were changed, says a new study. An investigation into why false negatives occur and how they could be reduced has found that there are quantitative differences between false negatives and true positives, according to a study in the latest issue of the Journal of Clinical Pathology (1999;52:358-62).
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.